Free-text search
Content Types
-
China seeks to block foreign acquisitions of biotech platforms
The Chinese government plans to introduce new rules to restrict foreign companies’ ability to acquire Chinese biotechnology.
-
A Biotech CTO on the Outsourcing Dilemma: “The Stakes Are Extremely High”
For small biotech companies, external expertise can be essential to moving drug development forward. But what happens when priorities shift, financing changes a...
-
Ulf Landegren: From scientific discovery to successful companies
He is a scientist, inventor and entrepreneur with a string of successful companies to his name. Now, Ulf Landegren, a professor at Uppsala University, is to rec...
-
Lilly’s new weight-loss pill recommended for EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued several new recommendations on medicines, including Eli L...
-
Danish health minister: Europe must act on China
Danish politicians and medtech industry representatives are calling for closer cooperation between hospitals and companies to boost innovation. Danish Health Mi...
-
AstraZeneca strikes 1.5 billion dollar AI drug discovery deal
AstraZeneca is entering into a strategic collaboration with US-based AI company insitro to identify novel drug targets and develop treatments for difficult-to-t...
-
EMA backs Revolution’s pancreatic cancer drug after rapid review
A new drug that has shown very promising results in metastatic pancreatic cancer has been recommended for approval in the EU following a record-fast review process.
-
Lundbeck sells off factory in Italy
Lundbeck has sold its Italian facility and will center ingredient manufacturing at home soil.
-
Finnish biotech raises 28 million euros for next-generation allergy treatments
Finnish biotech Desentum is developing a new type of immunotherapy for some of the most common allergies. The company has just raised 28 million euros in an ove...
-
GSK to cut 1,200 jobs in Belgium
More than 1,200 jobs at UK pharma giant GSK are at risk in Belgium as part of a major cost-cutting drive.
-
Modus shares halve after safety-related trial pause
Swedish biotech Modus Therapeutics has temporarily paused recruitment to its Phase IIa trial in anaemia associated with chronic kidney disease following a serio...
-
Swedish Life Science industry needs more than another funding wish list
When Swedish life science companies run into difficulties, calls for more public funding often follow. But do we really know what is holding these companies bac...
-
Your Partner for Clinical Study Submissions and Regulatory Interactions
Regulatory requirements are becoming increasingly complex, and managing submissions, amendments, and authority interactions can be both time consuming and resou...
-
Swedish electrode technology moves from lab to patients
Fractions of a millimetre can determine whether deep brain stimulation relieves symptoms or causes side effects. Now, after 20 years of research, scientists at ...
-
Oncopeptides raises SEK 100 million after brain cancer breakthrough
Swedish biotech Oncopeptides is raising SEK 100 million through a directed share issue. The announcement comes days after the company reported progress with its...
-
This is how Denmark wants to renegotiate the MDR
Danish health minister Ida Auken are heading to the EU to negotiate MDR, and Medtech Denmark are positive towards the government's position.
-
Teva wins FDA approval for schizophrenia injection
The US Food and Drug Administration (FDA) has approved Teva’s Weltruza, the first long-acting olanzapine injection that can be administered subcutaneously once ...
-
Cavidi Secures US Patent Allowance for BOLD Signal-Amplification Technology
The allowance protects Cavidi's Enzyme Enhanced ELISA invention in the US, five years after its first patent filing in Sweden.
-
Ambu expands their bronchoscopy offering
Ambu's bronchoscope offering has been cleared for use in the pediatric segment.
-
Xbrane reaches milestone with biosimilar to blockbuster cancer drug
Swedish biotech Xbrane is taking another step in developing a biosimilar to Bristol Myers Squibb’s blockbuster cancer drug Opdivo. All patients have now been en...
-
He helped build Oslo Cancer Cluster – now AI is his next challenge
After 12 years, Ketil Widerberg is stepping down as General Manager of Oslo Cancer Cluster. His next move takes him to Oslo University Hospital, where he will f...
-
Bristol Myers Squibb reports dual Phase III success
Bristol Myers Squibb has reported positive late-stage results for drug candidates targeting idiopathic pulmonary fibrosis and neuroendocrine tumours of the gast...
-
MMI raises $125M for robotic surgery
MMI, the maker of the Symani surgical robot, has completed a $125 million funding round.
-
Camurus takes next step with Oczyesa – wins Canadian approval
Swedish pharmaceutical company Camurus has secured another marketing approval for its acromegaly treatment. Canada has now approved Oczyesa XR, which patients c...
BREAKING